Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

le allowing Isis to continue to benefit as future milestones and commercial revenues are realized. By working closely with OncoGenex during the development of OGX-011, we have confidence that OncoGenex will independently maximize the value of OGX-011."

"The contributions of Isis have been instrumental in the development of OGX-011 to date and we anticipate that our positive interactions will continue with this amended relationship," added Cormack.

Under the terms of the original co-development agreement, OncoGenex paid 65% of the development costs and would receive 65% of any economic benefit resulting from the development of OGX-011. Under the terms of the amended agreement, Isis' funding commitment for 35% of the OGX-011 program ends, and OncoGenex will be responsible for all future development costs of OGX-011. These expenses have already been factored into OncoGenex' previously announced disclosures regarding anticipated development costs. Isis will receive royalties for OGX-011 ranging from 5.5% to 7% of net sales. In addition, OncoGenex will pay Isis 30% of the upfront fees and milestone payments OncoGenex receives if OncoGenex licenses OGX-011 prior to initiation of registration trials, 25% if OGX-011 is licensed before 20% of patients have been enrolled in a registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter.

OncoGenex recently announced preliminary Phase 2 data of OGX-011 in patients with hormone refractory prostate cancer at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators found that, in this patient population, OGX-011 continues to show better than expected survival results when compared to published results. OGX-011, also referred to as custirsen sodium, is a second-generation antisense oligonucleotide designed to facilitate tumor cell death induced by chemotherapy by decreasing production of clusterin, a cell survival protein linked to treatment res
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... A novel combination of microscopy and data processing has ... National Laboratory an unprecedented look at the surface of ... properties. , The research team led by ORNL,s ... a perovskite manganite, a complex material that exhibits dramatic ... surface behavior could benefit researchers who are interested in ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... research team led by group leader Yung-Eun Sung ... to synthesize sulfur-doped and nitrogen-doped graphenes which can ... batteries and fuel cells. Yung-Eun Sung is both ... Research at Institute for Basic Science* (IBS) and ... This achievement has great significance with regards to ...
(Date:7/24/2014)... synthetic processes prefer to settle into equilibriuma state ... within the realm of non-equilibrium conditions where new ... energy and phases, such as temperature fluctuations, freezing ... to regulate their body temperature, airplanes to fly, ... , But even though these conditions exist ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4New approach to form non-equilibrium structures 2
... Oct. 23 BioWisdom Ltd (BioWisdom),the market ... industry, today announces the release of OmniViz,Visualization ... are increasingly being used in competitive business ... business decisions.,OmniViz Visualization Software can turn the ...
... Israel and JERSEY CITY, New Jersey, October 23, ... in,the development of microRNA-based diagnostics and therapeutics, today,announced ... Annual,Meeting on "Molecular Markers in Cancer". The event ... in Hollywood, Florida., The poster presentation, titled ...
... FRANCISCO, Calif., Oct. 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... today announced that it will hold a conference ... provide a corporate update,including an update on the ... candidate., Jerry McMahon, Ph.D., chairman and chief ...
Cached Biology Technology:Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 2Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 3Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30 2
(Date:7/24/2014)... wildlife loss leads to conflict among people around the ... Society (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) ... approach to tackle global biodiversity decline. , The harvest ... world,s people and provides protein for more than a ... no surprise that today,s unprecedented loss of wildlife, is ...
(Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
(Date:7/24/2014)... Angeles, where electric cars ply silent freeways, solar panels ... beneath the earth, from howling winds and from the ... that it is technically and economically feasible to convert ... renewable energy. Published in Energy , the plan ... energy supply in California that could create tens of ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... French . Some of the human X chromosome ... Africa, according to an international team of researchers led by ... of Montreal and the CHU Sainte-Justine Research Center. The research ... and Evolution. "This confirms recent findings suggesting ...
... July 18, 2011 Researchers at UT Southwestern Medical ... involved in the formation of colon cancer, far more ... study, published in the July 2011 Cancer Research (Priority ... cancer treatments targeting multiple genes and pathways simultaneously. Current ...
... YORK, July 16, 2011 Experts from the Center ... Center will present new research at the 2011 Alzheimer,s ... in Paris, France from July 16 21. ... impairment in retired football players, with Stella Karantzoulis, PhD, ...
Cached Biology News:Genetic research confirms that non-Africans are part Neanderthal 2NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 2NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 3NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 4NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 5NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 6
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
... The LXQ linear ion trap mass spectrometer ... analytical laboratory., The LXQ linear ion trap ... and proteomic applications, delivering the fast cycle ... linear ion trap at an attractive price. ...
... scientists who do not have access to microarray ... their biological samples tested for the concentration of ... 1-2-3 Chose the analytes you wish ... S&S antibody menu. Send your samples to ...
... Persistent Analysis Environment 2) Dot plot, ... 3) Software Compensation 4) Cell Cycle ... Platform 7) Intelligent batch generation of graphs ... 9) Single drag-and-drop operations to perform complex ...
Biology Products: